Press Releases
November 15, 2021
Presentations Include Final Safety and Efficacy Data from the Phase 1b/2 Trial using Intravitreal Administration and Updated Safety Data from the Phase 2 Trial using Suprachoroidal Administration CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 15, 2021-- Aura Biosciences , a clinical-stage oncology
October 28, 2021
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 28, 2021-- Aura Biosciences, Inc. (“Aura”), a clinical-stage oncology company developing a novel class of virus-like drug conjugate therapies for multiple oncology indications, today announced the pricing of its initial public offering of 5,400,000 shares of
September 29, 2021
Chris Primiano, J.D., Appointed as Chief Business Officer Antony Mattessich Appointed to the Board of Directors CAMBRIDGE, MA – September 29, 2021  – Aura Biosciences, a clinical-stage oncology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology
June 17, 2021
Prominent, Multi-Disciplinary Clinicians and Scientists Bring Extensive Strategic Expertise in Urologic Oncology Across All Stages of Research and Development CAMBRIDGE, MA – June 17, 2021  – Aura Biosciences, a clinical-stage oncology company developing a novel class of virus-like drug conjugate
April 14, 2021
Results Support VDCs induction of Pro Immunogenic Cell Death and the Generation of Long Lasting Adaptive Anti-Tumor Immunity – Combination of VDCs with Checkpoint Inhibitors Achieves a High Complete Response Rate and Prevents Long Term Tumor Recurrence – CAMBRIDGE, MA – April 14, 2021  – Aura
Displaying 1 - 10 of 13